tiprankstipranks
Replimune Group’s Q3 2024 Financial Highlights
PremiumCompany AnnouncementsReplimune Group’s Q3 2024 Financial Highlights
9d ago
Replimune Group Navigates Clinical, Regulatory, and Market Challenges Amid Global Uncertainties
Premium
Company Announcements
Replimune Group Navigates Clinical, Regulatory, and Market Challenges Amid Global Uncertainties
10d ago
Replimune reports Q2 EPS (68c), consensus (77c)
Premium
The Fly
Replimune reports Q2 EPS (68c), consensus (77c)
11d ago
Replimune appoints Balachandran to board of directors
PremiumThe FlyReplimune appoints Balachandran to board of directors
3M ago
Replimune initiated with a Buy at Roth MKM
Premium
The Fly
Replimune initiated with a Buy at Roth MKM
3M ago
Replimune announces first patient dosed in IGNYTE-3 trial
Premium
The Fly
Replimune announces first patient dosed in IGNYTE-3 trial
3M ago
Replimune Group reports Q1 EPS (78c), consensus (85c)
PremiumThe FlyReplimune Group reports Q1 EPS (78c), consensus (85c)
4M ago
Replimune Group Secures Funding for Cancer Treatment Expansion
Premium
Company Announcements
Replimune Group Secures Funding for Cancer Treatment Expansion
5M ago
Replimune Group to sell 5.67M shares at $8.82 in private placement
Premium
The Fly
Replimune Group to sell 5.67M shares at $8.82 in private placement
5M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100